The U.S. Food and Drug Administration (FDA) has received the supplemental Biologics License Application (sBLA) submitted by Bristol-Myers Squibb Company for filing and revision of the company’s Yervoy. The medicinal product was designed as an adjuvant therapy for patients who suffer from stage 3 melanoma and are particularly at risk of recurrence after a resection surgical procedure.
MRV Research
Researchers create personalised vaccines for patients with advanced melanoma
A study has revealed that targeting patient-specific markers in advanced melanoma tumours effectively triggers an immune response
SLNB in pure desmoplastic melanoma remains controversial
Medically fit patients with mixed desmoplastic melanoma should be offered sentinel lymph node biopsy, according to a presenter at the HemOnc Today Melanoma and Cutaneous Malignancies meeting.
People with high-risk tumors containing BRAF or NRAS gene mutations have lower survival rates
Researchers from the UNC Lineberger Comprehensive Cancer Center analyzed hundreds of melanoma samples to find out if two genetic mutations more commonly found in melanoma tumors were associated with lower survival rates in patients.